Literature DB >> 22251925

Carbamazepine-induced hypogammaglobulinemia.

Nihal Ozaras1, Nadir Goksugur, Saliha Eroglu, Omur Tabak, Billur Canbakan, Resat Ozaras.   

Abstract

Carbamazepine is used to control seizures. Its common side effects are sleep disorders, anorexia, nausea, vomiting, polydipsia, irritability, ataxia, and diplopia. Involvement of the immune system is rare, and few cases of decreased immunoglobulin levels have been reported. We describe a patient with low immunoglobulin levels due to carbamazepine use who presented with recurrent urinary tract infection. Intravenous immunoglobulin was administered, and immunoglobulin levels increased to safer levels after discontinuation of carbamazepine. Previous reports describe severe infection after carbamazepine-induced hypogammaglobulinemia. Therefore, in patients using antiepileptics, particularly carbamazepine, serum immunoglobulin levels should be checked in those with recurrent infections. Copyright Â
© 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22251925     DOI: 10.1016/j.seizure.2011.12.013

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  4 in total

1.  Occurrence of pharmaceuticals, hormones, and perfluorinated compounds in groundwater in Taiwan.

Authors:  Yen-Ching Lin; Webber Wei-Po Lai; Hsin-hsin Tung; Angela Yu-Chen Lin
Journal:  Environ Monit Assess       Date:  2015-04-16       Impact factor: 2.513

2.  Valproate-induced panhypogammaglobulinemia.

Authors:  Tae-Hoon Eom; Hyun-Seung Lee; Pil-Sang Jang; Young-Hoon Kim
Journal:  Neurol Sci       Date:  2012-07-14       Impact factor: 3.307

Review 3.  The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in epileptic patient: a systematic review.

Authors:  Wefa Boughrara; Amina Chentouf
Journal:  Acta Neurol Belg       Date:  2022-03-24       Impact factor: 2.471

4.  Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement.

Authors:  Sai S Duraisingham; Matthew Buckland; John Dempster; Lorena Lorenzo; Sofia Grigoriadou; Hilary J Longhurst
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.